VIVE earnings

Total revenue of $1.7 million in Q3 including sale of 3,100 disposable treatment tipsPURSUIT clinical trial completion expected by year-endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / November 10, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of female stress urinary incontinence (SUI), today reported financial results for the quarter ended September 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the third quarter of 2022, we continued to make great progress in the final phase of our pivotal U.S. PURSUIT clinical trial fo

ENGLEWOOD, CO / ACCESSWIRE / October 27, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its third quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 10, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The third quarter 2022 results conference call may be accessed on Thursday, November 10th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://event.choruscall.com/mediaframe/we

Total revenue of $1.8 million in Q2 including sale of 2,850 disposable treatment tipsPURSUIT clinical trial follow-up visit completion anticipated by year endConference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / August 11, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today reported financial results for the quarter ended June 30, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the second quarter of 2022, we continued to advance our stress urinary incontinence (SUI) clinical development program. We

ENGLEWOOD, CO / ACCESSWIRE / July 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's health and the treatment of stress urinary incontinence (SUI), today announced that it will report its second quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 11, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The second quarter 2022 results conference call may be accessed on Thursday, August 11th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://event.choruscall.com/mediaframe/webcast

Total revenue of $1.6 million in Q1 including sale of 2,750 consumable treatment tipsPURSUIT trial top-line results anticipated at end of 2022Conference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / May 12, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended March 31, 2022, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the first quarter of 2022, we continued the focus on advancing our stress urinary incontinence (SUI) clinical development program. We remain on track to complete all patient follow-up vi

ENGLEWOOD, CO / ACCESSWIRE / April 28, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its first quarter 2022 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, May 12, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day. The first quarter 2022 results conference call may be accessed on Thursday, May 12th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://services.choruscall.com/mediaframe/webcast.html?webcastid=kTDfnY3F. Participants may also

Reported total revenue for year end 2021 of $6.4 million representing 17% year-over-year growthEnrollment completed in U.S. pivotal PURSUIT trial for stress urinary incontinence and 12-month post treatment follow-up visits underwayPURSUIT top-line results anticipated at end of 2022Conference call to be hosted by Company at 5:00 PM ET todayENGLEWOOD, CO / ACCESSWIRE / March 17, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the year ended December 31, 2021. The Company will provide a corporate update on its scheduled conference call at 5:00 PM ET today."I am extremely pleased with the milestones

ENGLEWOOD, CO / ACCESSWIRE / March 3, 2022 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its full year 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, March 17, 2022. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The full year 2021 results conference call may be accessed on Thursday, March 17th at 5:00 PM ET by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://services.choruscall.com/mediaframe/webcast.html?webcastid=NZykfofx. Participants may also registe

Total revenue of $1.6M reported for Q3Pivotal SUI PURSUIT trial enrollment nears completion - randomizations on-track for completion in Q4ENGLEWOOD, CO / ACCESSWIRE / November 11, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended September 30, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today. The Company's 10-Q documents will be filed on Friday, November 12, 2021, when the U.S. Securities and Exchange Commission reopens following the Veterans Day holiday."During the third quarter of 2021, we continued to make great progress in advancin

ENGLEWOOD, CO / ACCESSWIRE / November 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its third quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, November 11, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The Company's 10-Q documents will be filed on Friday, November 12, 2021, when the U.S. Securities and Exchange Commission reopens following the Veterans Day holiday.The third quarter 2021 results conference call may be accessed on Thursday, November 11th at 5:00 PM ET by dialing 1-833-

Total revenue of $1.7M reported for Q2Reported sales of approximately 3,500 consumable treatment tips - a 42% unit increase quarter-over-quarterPivotal SUI PURSUIT trial enrollment on-track for completion in early Q4Potential long-term reimbursement pathway established with new Category III CPT® codeENGLEWOOD, CO / ACCESSWIRE / August 12, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today reported financial results for the quarter ended June 30, 2021, and will provide a corporate update on its scheduled conference call at 5:00 PM ET today."During the second quarter of 2021, Viveve continued its focus on advancing its stress urina

ENGLEWOOD, CO / ACCESSWIRE / August 5, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it will report its second quarter 2021 financial results and provide a corporate update after the close of the U.S. financial markets on Thursday, August 12, 2021. The Company will hold a conference call and webcast at 5:00 PM ET the same day.The conference call may be accessed by dialing 1-833-255-2833 (domestic) or 1-412-902-6728 (international) or via live webcast at https://services.choruscall.com/links/vive210812.html. Participants may also pre-register for the conference call at https://dpregister.com/sreg/10158310/eaa98